Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021

Thrombosis with thrombocytopenia (TTS) has been identified as a rare adverse event following COVID-19 vaccination with Vaxzevria. We modelled the benefits and risks of Vaxzevria distribution from May to September 2021 in metropolitan France where other vaccines are available, considering French hosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran Kiem, Cécile, Andronico, Alessio, Bosetti, Paolo, Paireau, Juliette, Alter, Lise, Boëlle, Pierre-Yves, Fontanet, Arnaud, Lévy-Bruhl, Daniel, Cauchemez, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326661/
https://www.ncbi.nlm.nih.gov/pubmed/34212840
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.26.2100533
_version_ 1783731881230991360
author Tran Kiem, Cécile
Andronico, Alessio
Bosetti, Paolo
Paireau, Juliette
Alter, Lise
Boëlle, Pierre-Yves
Fontanet, Arnaud
Lévy-Bruhl, Daniel
Cauchemez, Simon
author_facet Tran Kiem, Cécile
Andronico, Alessio
Bosetti, Paolo
Paireau, Juliette
Alter, Lise
Boëlle, Pierre-Yves
Fontanet, Arnaud
Lévy-Bruhl, Daniel
Cauchemez, Simon
author_sort Tran Kiem, Cécile
collection PubMed
description Thrombosis with thrombocytopenia (TTS) has been identified as a rare adverse event following COVID-19 vaccination with Vaxzevria. We modelled the benefits and risks of Vaxzevria distribution from May to September 2021 in metropolitan France where other vaccines are available, considering French hospitalisation data and European data on TTS. Across different scenarios, benefits of Vaxzevria distribution in people 55 years and older exceeded the risk of death from COVID-19. In young adults, risks were at least of similar magnitude as benefits.
format Online
Article
Text
id pubmed-8326661
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-83266612021-08-11 Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021 Tran Kiem, Cécile Andronico, Alessio Bosetti, Paolo Paireau, Juliette Alter, Lise Boëlle, Pierre-Yves Fontanet, Arnaud Lévy-Bruhl, Daniel Cauchemez, Simon Euro Surveill Rapid Communication Thrombosis with thrombocytopenia (TTS) has been identified as a rare adverse event following COVID-19 vaccination with Vaxzevria. We modelled the benefits and risks of Vaxzevria distribution from May to September 2021 in metropolitan France where other vaccines are available, considering French hospitalisation data and European data on TTS. Across different scenarios, benefits of Vaxzevria distribution in people 55 years and older exceeded the risk of death from COVID-19. In young adults, risks were at least of similar magnitude as benefits. European Centre for Disease Prevention and Control (ECDC) 2021-07-01 /pmc/articles/PMC8326661/ /pubmed/34212840 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.26.2100533 Text en This article is copyright of the authors or their affiliated institutions, 2021. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Tran Kiem, Cécile
Andronico, Alessio
Bosetti, Paolo
Paireau, Juliette
Alter, Lise
Boëlle, Pierre-Yves
Fontanet, Arnaud
Lévy-Bruhl, Daniel
Cauchemez, Simon
Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021
title Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021
title_full Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021
title_fullStr Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021
title_full_unstemmed Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021
title_short Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021
title_sort benefits and risks associated with different uses of the covid-19 vaccine vaxzevria: a modelling study, france, may to september 2021
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326661/
https://www.ncbi.nlm.nih.gov/pubmed/34212840
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.26.2100533
work_keys_str_mv AT trankiemcecile benefitsandrisksassociatedwithdifferentusesofthecovid19vaccinevaxzevriaamodellingstudyfrancemaytoseptember2021
AT andronicoalessio benefitsandrisksassociatedwithdifferentusesofthecovid19vaccinevaxzevriaamodellingstudyfrancemaytoseptember2021
AT bosettipaolo benefitsandrisksassociatedwithdifferentusesofthecovid19vaccinevaxzevriaamodellingstudyfrancemaytoseptember2021
AT paireaujuliette benefitsandrisksassociatedwithdifferentusesofthecovid19vaccinevaxzevriaamodellingstudyfrancemaytoseptember2021
AT alterlise benefitsandrisksassociatedwithdifferentusesofthecovid19vaccinevaxzevriaamodellingstudyfrancemaytoseptember2021
AT boellepierreyves benefitsandrisksassociatedwithdifferentusesofthecovid19vaccinevaxzevriaamodellingstudyfrancemaytoseptember2021
AT fontanetarnaud benefitsandrisksassociatedwithdifferentusesofthecovid19vaccinevaxzevriaamodellingstudyfrancemaytoseptember2021
AT levybruhldaniel benefitsandrisksassociatedwithdifferentusesofthecovid19vaccinevaxzevriaamodellingstudyfrancemaytoseptember2021
AT cauchemezsimon benefitsandrisksassociatedwithdifferentusesofthecovid19vaccinevaxzevriaamodellingstudyfrancemaytoseptember2021

Ejemplares similares